<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02150707</url>
  </required_header>
  <id_info>
    <org_study_id>DPP4201401</org_study_id>
    <nct_id>NCT02150707</nct_id>
  </id_info>
  <brief_title>The Differential Effects of Diabetes Therapy on Inflammation</brief_title>
  <official_title>The Differential Effects of Diabetes Therapy on Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Irish Endocrine Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal College of Physicians</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University College Dublin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine if different diabetes treatments have different effects on
      inflammation; in particular, kidney inflammation. This type of inflammation is common in
      people with diabetes, and can lead to kidney failure. This study will investigate the effect
      of different types of diabetes treatment on kidney inflammation. This will help us to decide
      if certain types of medicine should be preferred in people with evidence of inflammation in
      their kidneys, as this may help prevent major complications including kidney failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective cohort study, patients who are clinically determined to require
      escalation of their glycaemic therapy, and prescribed a DPP4 inhibitor, GLP-1 receptor
      agonist, or insulin, will be invited to participate.

      Blood and urine samples will be taken before, 4 to 8 weeks after, and 26 weeks after starting
      the new therapy. Markers of inflammation, renal function and glycemic control will be
      measured at each timepoint.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albumin:creatinine ratio</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">17</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Dipeptidyl-Peptidase IV Inhibitors</arm_group_label>
    <description>Newly started on DPP4 inhibitor for hyperglycaemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucagon-Like Peptide 1</arm_group_label>
    <description>Newly started on GLP-1 for hyperglycaemia or obesity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipeptidyl-Peptidase IV Inhibitors</intervention_name>
    <description>Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia</description>
    <arm_group_label>Dipeptidyl-Peptidase IV Inhibitors</arm_group_label>
    <other_name>DPP4 inhibitors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon-Like Peptide 1</intervention_name>
    <description>Glucagon-Like Peptide 1 to treat hyperglycaemia</description>
    <arm_group_label>Glucagon-Like Peptide 1</arm_group_label>
    <other_name>Liraglutide</other_name>
    <other_name>Exenatide</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be a prospective cohort study with 120 participants: 40 per group. I have
        calculated this sample size to achieve a 90% power based on a 50% reduction in urinary
        chemokines and circulating pro-inflammatory immune cells 1-4. This power calculation
        anticipates a 10% dropout rate.

        Patients with DKD presenting to the diabetes service of St Vincent's University Hospital
        (SVUH) and Mater Misericordiae University Hospital (MMUH) who are commenced on GLP-1, DPP4i
        or insulin for the first time will be invited to participate in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 30 years

          -  Diagnosis of type 2 diabetes for one year or more

          -  Diagnosis of DKD as defined by two distinct albumin:creatinine ratio measurements
             above the gender specific range in the local reference laboratory with an interval of
             no less than eight week between measurements

          -  Stable dose of an inhibitor of the renin angiotensin system for a period of 8 weeks

        Exclusion Criteria:

          -  Any cognitive impediment that preclude the participant from giving free and informed
             consent

          -  Substance abuse including alcohol excess

          -  Use of a GLP-1 analogue in the last 6 months

          -  Pregnancy

          -  Hypersensitivity to the prescribed treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donal O'Shea, MD FRCPI</last_name>
    <role>Study Director</role>
    <affiliation>University College Dublin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carel W le Roux, PhD MB FRCP</last_name>
    <role>Study Director</role>
    <affiliation>University College Dublin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mensud Hatunic, MD MRCPI</last_name>
    <role>Study Director</role>
    <affiliation>University College Dublin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <reference>
    <citation>Fenske WK, Dubb S, Bueter M, Seyfried F, Patel K, Tam FW, Frankel AH, le Roux CW. Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis. 2013 Jul-Aug;9(4):559-68. doi: 10.1016/j.soard.2012.03.009. Epub 2012 Apr 10.</citation>
    <PMID>22608055</PMID>
  </reference>
  <reference>
    <citation>Hogan AE, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O'Connell J, O'Shea D. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2014 Apr;57(4):781-4. doi: 10.1007/s00125-013-3145-0. Epub 2013 Dec 21.</citation>
    <PMID>24362727</PMID>
  </reference>
  <reference>
    <citation>Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011;58(1):69-73. Epub 2010 Dec 28.</citation>
    <PMID>21206136</PMID>
  </reference>
  <reference>
    <citation>Wu JD, Xu XH, Zhu J, Ding B, Du TX, Gao G, Mao XM, Ye L, Lee KO, Ma JH. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011 Feb;13(2):143-8. doi: 10.1089/dia.2010.0048.</citation>
    <PMID>21284481</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>May 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College Dublin</investigator_affiliation>
    <investigator_full_name>Karl Neff</investigator_full_name>
    <investigator_title>Clinical Research Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

